Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention
Background Although there have been several studies related to serum fibroblast growth factor 21 (FGF21) levels and acute myocardial infarction, the value of serum FGF21 levels in ST-segment elevation myocardial infarction (STEMI) patients after emergency percutaneous coronary intervention (PCI) has...
Main Authors: | Lingyun Gu, Wenlong Jiang, Huidong Qian, Ruolong Zheng, Weizhang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2021-09-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/12235.pdf |
Similar Items
-
An Innovative Scoring System for Predicting Major Adverse Cardiac Events in Patients With Chest Pain Based on Machine Learning
by: Chieh-Chen Wu, et al.
Published: (2020-01-01) -
Cardiac Rehabilitation of Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in a Han Population in Northern China: A Prospective Cohort Study
by: Ma J, et al.
Published: (2021-08-01) -
The relationship between Fibroblast Growth Factor 23 (FGF23) and cardiac MRI findings following primary PCI in patients with acute first time STEMI
by: Inga Strand Thorsen, et al.
Published: (2021-04-01) -
Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI
by: Chen Die Yang, et al.
Published: (2020-09-01) -
The relationship between low thiol levels and major adverse cardiovascular events after primary percutaneous coronary intervention in patients with STEMI
by: Oğuz Akkuş, et al.
Published: (2018-05-01)